Yale Cancer Center study suggests new approaches needed to manage ibrutinib-related toxicities in CLL patients

New findings by Yale Cancer Center (YCC) and Smilow Cancer Hospital researchers show that as the use of the drug ibrutinib climbs in patients with chronic lymphocytic leukemia (CLL), so do the rates of patients who stop taking the drug.

Read more